Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06476132 · ClinicalTrials.gov registry record · Phase 2

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

A Phase 2 study of Lung Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Recruiting
Registry status
Phase 2
Development phase
234
Enrollment target
10
Study locations

NCT06476132 is a Phase 2 study of Lung Transplant that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 234 participants, below the 1,261-participant average among 15 other Lung Transplant trials with a reported enrollment target (81% lower). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06476132, a Phase 2 study of Lung Transplant, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

RECRUITING
Registry status
Phase 2
Development phase
234 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to see if taking the study drug, Belumosudil, for 52 weeks in addition to your usual care and medication, will prevent Chronic Lung Allograft Dysfunction (CLAD) in participants who have a lung biopsy that shows evidence of rejection or inflammation to the transplanted lung(s). For this study, biopsies that show evidence of Acute Rejection (AR), Lymphocytic Bronchiolitis (LB), Organizing Pneumonia (OP) or Acute Lung Injury (ALI) are referred to as "Qualifying Biopsies"; patients who had evidence of one or more of these conditions on a recent biopsy are eligible for enrollment in this study. Belumosudil is an investigational drug that blocks a molecule in the body that reduces inflammation and scarring and may play a role in the development and progression of CLAD. Belumosudil is a drug approved by the FDA to treat adults and children 12 years and older with chronic graft-versus-host disease (cGVHD), a condition with some similarities to CLAD. The primary objective it to determine the efficacy of treatment with Belumosudil + maintenance immunosuppression (IS) versus placebo + maintenance IS on preventing the subsequent development of probable or definite CLAD, lung retransplant, or death.

Conditions Studied

Lung Transplant

Interventions

  • DRUG Belumosudil
  • DRUG Placebo for Belumosudil

Study Locations (10)

Ohio

  • Cincinnati Children's Hospital Medical Center (Site #: 71017) - Cincinnati
  • Cleveland Clinic (Site #: 71101) - Cleveland

California

  • University of California, Los Angeles (Site #: 71123) - Los Angeles

Maryland

  • Johns Hopkins (Site #: 71119) - Baltimore

Minnesota

  • University of Minnesota (Site 71151) - Minneapolis

Missouri

  • Washington University (Site #: 71157) - St Louis

New York

  • NYU Langone Health (Site #: 71177) - New York

North Carolina

  • Duke University (Site #: 71139) - Durham

Pennsylvania

  • University of Pennsylvania (Site #: 71111) - Philadelphia

Trial Details

FieldValue
Enrollment Target 234 participants
Start Date 2025-03-12
Est. Completion 2027-06-30
Phase Phase 2

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06476132

The ClinicalTrials.gov registry entry for NCT06476132 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,261-participant average among 15 other Lung Transplant trials with a reported enrollment target (81% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Transplant appearing as the primary indexed condition, and to 2 interventions - of which Belumosudil is the first listed.

NCT06476132 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Ohio, California, Maryland.

Frequently Asked Questions

What is clinical trial NCT06476132 about?

NCT06476132 is a clinical study titled "Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients". The purpose of this study is to see if taking the study drug, Belumosudil, for 52 weeks in addition to your usual care and medication, will prevent Chronic Lung Allograft Dysfunction (CLAD) in participants who have a lung biopsy that shows evidence of rejection or inflammation to the transplanted lu...

What is the current status of trial NCT06476132?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2025-03-12. Estimated completion is 2027-06-30.

What conditions does trial NCT06476132 study?

This clinical trial studies the following conditions: Lung Transplant.

What interventions are being tested in trial NCT06476132?

The interventions under investigation include: Belumosudil (DRUG), Placebo for Belumosudil (DRUG).

Who is sponsoring clinical trial NCT06476132?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06476132 being conducted?

This trial has 10 study locations across California, Maryland, Minnesota, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Transplant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Transplant

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.